Entering text into the input field will update the search result below

Antares Pharma, Inc. (ATRS) CEO Robert Apple on Q1 2020 Results - Earnings Call Transcript

May 05, 2020 1:03 PM ETHalozyme Therapeutics, Inc. (HALO)2 Comments
SA Transcripts profile picture
SA Transcripts

Antares Pharma, Inc. (ATRS) Q1 2020 Earnings Conference Call May 5, 2020 8:30 AM ET

Company Participants

John Howarth - VP, Corporate Affairs

Robert Apple - CEO, President & Director

Fred Powell - EVP & CFO

Conference Call Participants

Kenneth Cacciatore - Cowen and Company

Elliot Wilbur - Raymond James & Associates

David Amsellem - Piper Sandler & Co.

Anthony Petrone - Jefferies

Oren Livnat - H.C. Wainwright & Co.


Ladies and gentlemen, welcome to the Antares Pharma First Quarter 2020 Operating and Financial Results Conference Call. [Operator Instructions].

I will now hand the conference over to Jack Howarth, Antares' Vice President of Corporate Affairs. Please go ahead, sir.

John Howarth

Thank you, Jonathan, and good morning, everyone. Earlier today, we announced our first quarter 2020 financial results and operating achievements. A copy of the press release and slide presentation for today's conference call are available on the Investors section of the Antares website.

Before we begin, I'd like to remind you that some of our statements made during this conference call will contain forward-looking statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements include those related to our future financial and operating results, including our expectations regarding the impact of the COVID-19 pandemic and mitigation measures implemented in response to the outbreak, on our product supply, demand for our products, new patients and future prescriptions, future revenue, development programs and our overall business, operating results and financial condition, the adverse effect of the COVID-19 pandemic on the global economy and financial markets and the potential adverse effect on our future business and operations; future revenue growth, prescription volumes and market share for our products, new product approvals and launches, FDA actions and other regulatory activities, results of ongoing and future clinical trials and other product development activities and business development

Recommended For You

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.